Cite this article:
Gautam and Suresh (2016). Enteric Coated Microparticulate System: Novel Approach for the Treatment of Osteoporosis. Journal of Ravishankar University (Part-B: Science), 29(1), pp.152-153.
PP-C16
Enteric Coated
Microparticulate System: Novel Approach for the Treatment of Osteoporosis
Nivedita Gautam and Preeti K
Suresh
Institute of Pharmaceutical
Sciences, Guru Ghasidas Vishwavidyalaya, Bilaspur - 495 006, India
Corresponding author email:
gautamnivedita89@gmail.com
[Received
15 January 2016, accepted 06 February 2016]
Abstract: Osteoporosis
is a major problem worldwide especially in postmenopausal women and is treated
with bisphosphonates. The drug belongs to BCS class II, and thus has high
solubility and low permeability and has severe gastric ulceration side effects.
To overcome these problems Risedronate (drug) loaded in microsphere in an
enteric coated formulation were prepared. Microparticles were prepared by
simple emulsification technique based on glutaraldehyde crosslinking and were
coated with Eudragit L-100. The microspheres were characterized for entrapment efficiency,
drug loading, in vitro drug release, surface morphology, as well as particle
size analysis, and FTIR spectroscopy. Particle sizes, as measured by the
optical microscopic technique, were of an average size in the range 200 um to
320 um with drug content 5.02- 9.88 and entrapment efficiency upto 82%. FTIR
data signifies no interaction between the drug and polymer used. In vitro
release studies were performed into phosphate buffers (pH 1.2 for 2 hr and pH
6.8 at 37°C) as a function of cross linking coating density of the
microspheres. Less than 10 % release was at pH 1.2 which confirms the enteric
coating of microsphers. Drug release was in the range of 65- 80% in 6 hrs and
follows Higuchi release kinetics. The findings of the present study conclusively
state that enteric coated microspheres of Risedronate are potential for
restricting drug release in stomach and sustained drug delivery in intestinal
region avoiding the gastric iritation effect of Risedronate.
Keywords:
Osteoporosis, Risedronate, Microsparticles, Enteric coating. In vitro release